The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression.

Several members of the ETS family of transcription factors contribute to tumorigenesis in many different tissues, including breast epithelium. The ESX gene is an epithelial-specific Ets member that is particularly relevant to breast cancer. ESX is amplified in early breast cancers, it is overexpressed in human breast ductal carcinoma in situ, and there may be a positive feedback loop between the HER2/neu proto-oncogene and ESX. Despite this progress in our understanding of ESX, its ability to regulate tumor-related gene expression and to modulate breast cell survival, remain unknown. Here we show that HA-ESX stimulates the collagenase and HER2/neu promoters, but fails to activate an intact stromelysin promoter. However, HA-ESX activates, in a dose-dependent manner, a heterologous promoter containing eight copies of the Ets binding site derived from the stromelysin gene (p8Xpal-CAT). Analysis of the ability of constructs encoding nine Ets family members to activate the HER2/neu promoter revealed three patterns of gene activation: (1) no effect or repressed promoter activity (Elk-1 and NET); (2) intermediate activity (ER81, GABP, ESX, and HA-Ets-2); and, (3) maximal activity (Ets-1, VP-16-Ets-1, and EHF). Based on these observations, we also determined whether ESX is capable of conferring a survival phenotype upon immortalized, but nontransformed and ESX negative MCF-12A human breast cells. Using a colony formation assay, we found that HA-ESX and HA-Ets-2, mediated MCF-12A cell survival rates that approached those generated by oncogenic V12 Ras, whereas empty vector resulted in negligible colony formation. By contrast, in immortalized and transformed T47D breast cancer cells, which express both HER2/neu and ESX, we found that antisense and dominant-negative HA-ESX inhibited T47D colony formation, whereas control vector allowed formation of many colonies. These results are significant because they show that HA-ESX is able to differentially activate several malignancy-associated gene promoters, and that ESX expression is required for cellular survival of nontransformed MCF-12A and transformed T47D human mammary cells.

[1]  K. Fujikawa,et al.  The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor , 1998, International journal of cancer.

[2]  A. Cano,et al.  Regulation of E-cadherin gene expression during tumor progression: the role of a new Ets-binding site and the E-pal element. , 1999, Experimental cell research.

[3]  L. McIntosh,et al.  Secondary structure of the ETS domain places murine Ets-1 in the superfamily of winged helix-turn-helix DNA-binding proteins. , 1994, Biochemistry.

[4]  B. Wasylyk,et al.  Interaction of Ets-1 and the POU-homeodomain protein GHF-1/Pit-1 reconstitutes pituitary-specific gene expression , 1997, Molecular and cellular biology.

[5]  B. Wasylyk,et al.  Functional interaction of c-Ets-1 and GHF-1/Pit-1 mediates Ras activation of pituitary-specific gene expression: mapping of the essential c-Ets-1 domain , 1995, Molecular and cellular biology.

[6]  B. Graves,et al.  Specificity within the ets family of transcription factors. , 1998, Advances in cancer research.

[7]  B. Wasylyk,et al.  Reversion of Ras transformed cells by Ets transdominant mutants. , 1994, Oncogene.

[8]  C. Hauser,et al.  Oncogenic Neu/ErbB-2 Increases Ets, AP-1, and NF-B-dependent Gene Expression, and Inhibiting Ets Activation Blocks Neu-mediated Cellular Transformation (*) , 1996, The Journal of Biological Chemistry.

[9]  R. Cardiff,et al.  A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. , 1999, Cancer research.

[10]  W. Herr,et al.  Reconstitution of transcriptional activation domains by reiteration of short peptide segments reveals the modular organization of a glutamine-rich activation domain , 1994, Molecular and cellular biology.

[11]  W. Muller,et al.  PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas. , 1993, Oncogene.

[12]  Y. Bang,et al.  A Novel ets-related Transcription Factor, ERT/ESX/ESE-1, Regulates Expression of the Transforming Growth Factor-β Type II Receptor* , 1998, The Journal of Biological Chemistry.

[13]  D. Leprince,et al.  A putative second cell-derived oncogene of the avian leukaemia retrovirus E26 , 1983, Nature.

[14]  A. Seth,et al.  The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated. , 1990, Oncogene.

[15]  R. Neve,et al.  The epithelium‐specific Ets transcription factor ESX is associated with mammary gland development and involution , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  R. Colman,et al.  Thrombin-induced Platelet Aggregation Is Inhibited by the Heptapeptide LeuAla of Domain 3 in the Heavy Chain of High Molecular Weight Kininogen (*) , 1996, The Journal of Biological Chemistry.

[17]  N. Brünner,et al.  Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines , 1997, Clinical & Experimental Metastasis.

[18]  M. Roussel,et al.  Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. , 1994, Oncogene.

[19]  K. Chew,et al.  HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer , 1997, Oncogene.

[20]  C. Albanese,et al.  Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.

[21]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[22]  S. Hirohashi,et al.  Cloning and Characterization of the Human β4-Integrin Gene Promoter and Enhancers* , 1998, The Journal of Biological Chemistry.

[23]  I. Maxwell,et al.  A DNA cassette containing a trimerized SV40 polyadenylation signal which efficiently blocks spurious plasmid-initiated transcription. , 1989, BioTechniques.

[24]  L. McIntosh,et al.  Solution structure of the ETS domain from murine Ets‐1: a winged helix‐turn‐helix DNA binding motif. , 1996, The EMBO journal.

[25]  M. Abe,et al.  ETS‐1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin β3 , 1999, Journal of cellular physiology.

[26]  M. Gilman,et al.  Distinct protein targets for signals acting at the c-fos serum response element. , 1991, Science.

[27]  R. Sager,et al.  Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[28]  C. Hauser,et al.  Oncogenic Ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites. , 1994, Oncogene.

[29]  J. Hassell,et al.  Role of Ets Transcription Factors in Mammary Gland Development and Oncogenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[30]  R. Maki,et al.  Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells. , 1994, The Journal of biological chemistry.

[31]  A. Nordheim,et al.  Ets transcription factors and human disease. , 1998, Biochimica et biophysica acta.

[32]  B. Haugen,et al.  Pit-1 and GATA-2 Interact and Functionally Cooperate to Activate the Thyrotropin β-Subunit Promoter* , 1997, The Journal of Biological Chemistry.

[33]  C. López-Otín,et al.  Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13). , 1997, Genomics.

[34]  M. Hung,et al.  The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis , 2000, Nature Medicine.

[35]  R. Treisman.  The serum response element. , 1992, Trends in biochemical sciences.

[36]  Wen-Lin Kuo,et al.  ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis , 1997, Oncogene.

[37]  Michael C. Ostrowski,et al.  GHF-1/Pit-1 Functions as a Cell-specific Integrator of Ras Signaling by Targeting the Ras Pathway to a Composite Ets-1/GHF-1 Response Element* , 1996, The Journal of Biological Chemistry.

[38]  P. Steinert,et al.  The expression of a novel, epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis. , 1997, Nucleic acids research.

[39]  T. Libermann,et al.  Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family , 1997, Molecular and cellular biology.

[40]  T. Libermann,et al.  Genomic organization of the human ELF3 (ESE-1/ESX) gene, a member of the Ets transcription factor family, and identification of a functional promoter. , 1999, Genomics.

[41]  K. Brodsky,et al.  The Pit-1 Homeodomain and β-Domain Interact with Ets-1 and Modulate Synergistic Activation of the Rat Prolactin Promoter* , 2000, The Journal of Biological Chemistry.

[42]  C. Albanese,et al.  Epidermal Growth Factor and c-Jun Act via a Common DNA Regulatory Element to Stimulate Transcription of the Ovine P-450 Cholesterol Side Chain Cleavage (CYP11A1) Promoter (*) , 1995, The Journal of Biological Chemistry.

[43]  B. Vandenbunder,et al.  The expression of an Ets1 transcription factor lacking its activation domain decreases uPA proteolytic activity and cell motility, and impairs normal tubulogenesis and cancerous scattering in mammary epithelial cells. , 1998, Journal of cell science.

[44]  B. Wasylyk,et al.  The c‐Ets oncoprotein activates the stromelysin promoter through the same elements as several non‐nuclear oncoproteins. , 1991, The EMBO journal.

[45]  R. Sutherland,et al.  Expression of the PEA3 group of ETS‐related transcription factors in human breast‐cancer cells , 1997, International journal of cancer.

[46]  J. Hassell,et al.  The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase , 1998, Oncogene.

[47]  H. Soule,et al.  Characterization of epithelial phenotypes in mortal and immortal human breast cells , 1992, International journal of cancer.

[48]  B. Wasylyk,et al.  Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. , 1998, Trends in biochemical sciences.

[49]  Martin Rosenberg,et al.  A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer , 1997, Oncogene.

[50]  C. Benz,et al.  Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP) , 1999, Oncogene.

[51]  A. Seth,et al.  ETS target genes: identification of egr1 as a target by RNA differential display and whole genome PCR techniques. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Karin,et al.  Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor , 1987, Cell.

[53]  Michael C. Ostrowski,et al.  Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression , 1992, Molecular and cellular biology.

[54]  B. Ljung,et al.  The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. , 1992, Oncogene.

[55]  C. Hauser,et al.  Elevated Expression of Ets2 or Distinct Portions of Ets2 Can Reverse Ras-mediated Cellular Transformation* , 1998, The Journal of Biological Chemistry.

[56]  J. Chambard,et al.  The Ets2 Transcription Factor Inhibits Apoptosis Induced by Colony-Stimulating Factor 1 Deprivation of Macrophages through a Bcl-xL-Dependent Mechanism , 1999, Molecular and Cellular Biology.